Literature DB >> 1352502

Genetic control of nonresponsiveness to hepatitis B virus vaccine by an extended HLA haplotype.

K Hatae1, A Kimura, R Okubo, H Watanabe, H A Erlich, K Ueda, Y Nishimura, T Sasazuki.   

Abstract

We previously reported evidence for a statistical association between the serologically determined HLA-Bw54, DR4 and DRw53 alleles and the non-immune responsiveness to hepatitis B virus surface antigen (HBsAg) in the Japanese population. To identify the locus and allele within the HLA region associated with the nonresponsiveness to HBsAg, serological HLA typing, DNA typing of HLA-DQ and DP alleles using amplified HLA genes and sequence-specific oligonucleotide probes, and restriction fragment length polymorphism (RFLP) analysis of the fourth component of complement (C4) genes were performed in healthy unrelated Japanese vaccinees who were immunized subcutaneously three times with plasma-derived HBsAg vaccine. In nonresponders to HBsAg, the frequencies of HLA-Bw54 cross-reactive epitope group (CREG); (Bw54, Bw55, Bw56 and other Bw22), C4 RFLP (6.5 kb + 12.0 kb), DR4, DRw53 and DQw4 (DQA1*0301-DQB1*0401) were increased and the frequencies of HLA-DR1, DRw6 and DQw1 were decreased as compared with those in healthy unrelated controls. Further analysis revealed that the coexistence of HLA-Bw54CREG and DR4-DRw53-DQw4 (DQA1*0301-DQB1*0401) was associated with the nonresponder group, whereas, donors positive for exclusively either Bw54 CREG or DR4-DRw53-DQw4 (DQA1*0301-DQB1*0401) were not associated with the nonresponder group. Because there is a strong linkage disequilibrium between HLA-Bw54CREG, C4 RFLP (6.5 kb + 12.0 kb) and HLA-DR4-DRw53-DQw4 (DQA1*0301-DQB1*0401) in the Japanese population, the extended HLA-Bw54CREG-C4 RFLP (6.5 kb + 12.0 kb)-DR4-DR-w53-DQw4 (DQA1*0301-DQB1*0401) haplotype may well control nonimmune responsiveness to HBsAg. This extended HLA haplotype controls nonresponsiveness as a dominant genetic trait because all ten heterozygotes and two of three probable homozygotes of this extended HLA haplotype were nonresponders.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1352502     DOI: 10.1002/eji.1830220733

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  10 in total

Review 1.  Use of licensed vaccines for active immunization of the immunocompromised host.

Authors:  L A Pirofski; A Casadevall
Journal:  Clin Microbiol Rev       Date:  1998-01       Impact factor: 26.132

2.  HLA-DPB1 and anti-HBs titer kinetics in hepatitis B booster recipients who completed primary hepatitis B vaccination during infancy.

Authors:  T-W Wu; C-C Chu; H-W Chang Liao; S-K Lin; T-Y Ho; M Lin; H H Lin; L-Y Wang
Journal:  Genes Immun       Date:  2013-11-28       Impact factor: 2.676

3.  Clear and independent associations of several HLA-DRB1 alleles with differential antibody responses to hepatitis B vaccination in youth.

Authors:  Yufeng Li; Rong Ni; Wei Song; Wenshuo Shao; Sadeep Shrestha; Sushma Ahmad; Coleen K Cunningham; Patricia M Flynn; Bill G Kapogiannis; Craig M Wilson; Jianming Tang
Journal:  Hum Genet       Date:  2009-07-14       Impact factor: 4.132

4.  Association between HLA DQB1 * 03 and cervical intra-epithelial neoplasia.

Authors:  K Odunsi; G Terry; L Ho; J Bell; J Cuzick; T S Ganesan
Journal:  Mol Med       Date:  1995-01       Impact factor: 6.354

Review 5.  A comparative review of HLA associations with hepatitis B and C viral infections across global populations.

Authors:  Rashmi Singh; Rashmi Kaul; Anil Kaul; Khalid Khan
Journal:  World J Gastroenterol       Date:  2007-03-28       Impact factor: 5.742

6.  Responses to booster hepatitis B vaccination are significantly correlated with genotypes of human leukocyte antigen (HLA)-DPB1 in neonatally vaccinated adolescents.

Authors:  Tzu-Wei Wu; Chen-Chung Chu; Tzu-Ying Ho; Huei-Wen Chang Liao; Sheng-Kai Lin; Marie Lin; Hans Hsienhong Lin; Li-Yu Wang
Journal:  Hum Genet       Date:  2013-06-06       Impact factor: 4.132

7.  Key HLA-DRB1-DQB1 haplotypes and role of the BTNL2 gene for response to a hepatitis B vaccine.

Authors:  Nao Nishida; Masaya Sugiyama; Hiromi Sawai; Sohji Nishina; Aiko Sakai; Jun Ohashi; Seik-Soon Khor; Keisuke Kakisaka; Takayo Tsuchiura; Keisuke Hino; Ryo Sumazaki; Yasuhiro Takikawa; Kazumoto Murata; Tatsuo Kanda; Osamu Yokosuka; Katsushi Tokunaga; Masashi Mizokami
Journal:  Hepatology       Date:  2018-04-27       Impact factor: 17.425

8.  Antibodies to hepatitis B virus surface antigen and interleukin 12 and interleukin 18 gene polymorphisms in hemodialysis patients.

Authors:  Alicja E Grzegorzewska; Piotr M Wobszal; Adrianna Mostowska; Paweł P Jagodziński
Journal:  BMC Nephrol       Date:  2012-08-03       Impact factor: 2.388

9.  Hepatitis B vaccination in chronic kidney disease: review of evidence in non-dialyzed patients.

Authors:  Alicja E Grzegorzewska
Journal:  Hepat Mon       Date:  2012-11-14       Impact factor: 0.660

10.  Host genetic factors and vaccine-induced immunity to hepatitis B virus infection.

Authors:  Branwen J Hennig; Katherine Fielding; John Broxholme; Mathurin Diatta; Maimuna Mendy; Catrin Moore; Andrew J Pollard; Pura Rayco-Solon; Giorgio Sirugo; Marianne A van der Sande; Pauline Waight; Hilton C Whittle; Syed M Zaman; Adrian V Hill; Andrew J Hall
Journal:  PLoS One       Date:  2008-03-26       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.